Chapter 8
Discovery and Development of Montelukast (Singulair®)
Robert N. Young,
Robert N. Young
Department of Chemistry, Simon Fraser University, Burnaby, British Columbia, Canada, V5A 1S6
Search for more papers by this authorRobert N. Young,
Robert N. Young
Department of Chemistry, Simon Fraser University, Burnaby, British Columbia, Canada, V5A 1S6
Search for more papers by this authorBook Editor(s):Xianhai Huang, Robert G. Aslanian,
Summary
This chapter contains sections titled:
-
Introduction
-
Drug Development Strategies
-
LTD4 Antagonist Program
-
The Discovery of Montelukast (Singulair®)
-
Synthesis of Montelukast
-
ADME Studies with MK-0476 (Montelukast)
-
Safety Assessment of Montelukast
-
Clinical Development of Montelukast
-
Summary
-
Personal Impact
-
References
REFERENCES
- ROKACH, J. Leukotrienes and Lipoxygensases, Chemical, Biological and Clinical Aspects (ed J. Rokach), Elsevier, Amsterdam, 1989.
- (a) FELDBERG, W., and KELLAWAY, C. H. Liberation of histamine and formation of lyscithin-like substances by cobravenom. J.Physiol. 1938, 94, 187–226. (b) FELDBERG, W., HOLDEN, H. F., and KELLAWAY, C. H. The formation of lyscithin and of a muscle-stimulating substance by snake venoms. J. Physiol. 1938, 94, 232–248.
- BROCKLEHURST, W. E., The release of histamine and formation of a slow reacting substance (SRS-A) during anaphylactic shock. J. Physiol. 1960, 151, 416–435.
- MORRIS, H. R., TAYLOR, G. W., PIPER, P. J., SIROIS, P., and TIPPINS, J. R. Slow-reacting substance of anaphylaxis: purification and characterization. FEBS Lett. 1978, 87, 203–206.
- BORGEAT, P. and SAMUELSSON, B. Metabolism of arachidonic acid in polymorphonuclear leukocytes. Structural analysis of novel hydroxylated compounds. J. Biol. Chem. 1979, 254, 7865–7869.
- MURPHY, R. C., HAMMARSTRÖM, S., and SAMUELSSON, B. LEUKOTRIENE C: a slow-reacting substance from murine mastocytoma cells. Proc. Natl. Acad. Sci. USA 1979, 76, 4275.
- COREY, E. J., CLARK, D. A., GOTO, G., MARFAT, A., MIOSKOWSKI, C., SAMUELSSON, B., and HAMMARSTRÖM, S. Stereospecific total synthesis of a “slow reacting substance” of anaphylaxis, leukotriene C-1. J. Am. Chem. Soc. 1980, 102, 1436–1439.
- ROKACH J. GIRARD Y, GUINDON Y, ATKINSON J. G. LAUE, M., YOUNG, R. N., MASSON, P., and HOLME, G. The synthesis of a leukotriene with SRS-like activity. Tetrahedron Lett. 1980, 21, 1485–1488.
- SAMUELSSON, B., and HAMMARSTRÖM, S. Nomenclature for leukotrienes. Prostaglandins 1980, 19, 645–646.
- CZARNETZKI, B. M., and ROSENBACH, T. From eosinophil chemotactic factor of anaphylaxis to leukotriene B4— chemistry, biology and functional significance of eosinophil chemotactic leukotrienes in dermatology. Dermatologica 1989, 179 Suppl 1, 54–59.
- (a) ROKACH, J., ZAMBONI, R., LAU, C. K., and GUINDON, Y. The stereospecific synthesis of leukotriene A4 (LTA4), 5-epi-LTA4, 6-epi-LTA4 and 5-epi, 6-epi-LTA4. Tetrahedron Lett. 1981, 22, 2759–2762; (b) ROKACH, J., ZAMBONI, R., and GUINDON, Y. Synthesis of the four optical isomers of LTA4 Tetrahedron Lett. 1981, 22, 2763–2766; (c) ROKACH, J., YOUNG, R. N., KAKUSHIMA, M., LAU, C. K., SEGUIN, R., FRENETTE, R., and GUINDON, Y. Synthesis of leukotrienes new synthesis of natural leukotriene A4, Tetrahedron Lett. 1981, 22, 979–982.
- FOSTER, A., FITZSIMMONS, B., and LETTS, L. G. The synthesis of N-acetyl-leukotriene E4 and its effects on cardiovascular and respiratory function of the anesthetized pig. Prostaglandins 1986, 31, 1077–1086.
- DELORME, D., GIRARD, Y., and ROKACH, J. Total synthesis of leukotriene E4 metabolites and precursors to radiolabeled forms of those metabolites. J. Org. Chem. 1989, 54, 3635–3640.
- MAMER, O., JUST, G., LI, C.-S., PRÉVILLE, P., WATSON, S., YOUNG, R., and YERGEY, J. A. Enhancement of mass spectrometric detection of LTC4, LTD and LTE by derivatization. J. Am. Soc. Mass Spectrom. 1994, 5, 292–298.
- (a) YOUNG, R. N., KAKUSHIMA M., and ROKACH, J. Studies on the preparation of conjugates of leukotriene C4 with proteins for the development of an immunoassay for SRSA (1). Prostaglandins 1982, 23, 603–613; (b) HAYES, E. C., GIRARD, Y., LOMBARDO, D. L., MAYCOCK, A. L., ROKACH, J., ROSENTHAL, A. S., YOUNG, R. N., EGAN R. W., and ZWEERINK, H. J. Measuring leukotrienes of slow reacting substance of anaphylaxis: development of a specific radioimmunoassay. J. Immunol. 1983, 131, 429–433; (c) YOUNG, R. N., ZAMBONI, R., and ROKACH, J. Studies on the conjugation of leukotriene B4 with proteins for development of a radioimmunoassay for leukotriene B4. Prostaglandins, 1983, 26, 605–613; (d) J. ROKACH, HAYES, E. C., GIRARD, Y., LOMBARDO, D. L., MAYCOCK, A. L., ROSENTHAL, A. S., YOUNG, R. N., ZAMBONI, R., and ZWEERINK, H. J. The development of sensitive and specific radioimmunoassays for leukotrienes H. J. Prostaglandins Leukotrienes Med. 1984, 13, 21–25.
- MILLER, D. K., SADOWSKI, S., DESOUSA, D., MAYCOCK, A. L., LOMBARDO, D., YOUNG, R. N., and HAYES, E. Development of enzyme-linked immunosorbant assays for measurement of leukotrienes and prostaglandins. J. Immunol. Methods 1985, 81, 169–185.
- (a) LEWIS, R. A., AUSTEN, K. F., DRAZEN, J. M., CLARK, D. A., MARFAT, A., and COREY, E. J. Slow reacting substances of anaphylaxis: identification of leukotrienes C-1 and D from human and rat sources. Proc. Natl Acad. Sci. USA, 1980, 77, 3710–3714; (b) MORRIS, H. R., TAYLOR, G. W., PIPER, P. J., and TIPPINS, J. R. Structure of slow-reacting substance of anaphylaxis from guinea-pig lung. Nature (London) 1980, 285, 104–106.
- (a) DRAZEN, J. M., AUSTEN, K. F., LEWIS, R. A., CLARK, D. A., GOTO, G., MARFAT, A., and COREY, E. J. Comparative airway and vascular activity of leukotriene C-1 and D in vivo and in vitro. Proc. Natl Acad. Sci. USA, 1980, 77, 4345–4358; (b) PIPER, P. J. Leukotrienes: potent mediators of airway constriction. Int. Arch. Allergy Immunol. 1985, 76(Suppl.I) 43–48;. (c) SNYDER, D. W. and FLEISCH, J. H. Leukotriene receptor antagonists as potential therapeutic agents. Ann. Rev. Pharmacol. Toxicol. 1989, 29, 123–143.
- HOFFSTEIN, S.T., MALO, P. E., BUGELSKI, P., and WHEELDON, E. B. Leukotriene D4 (LTD4) induces mucus secretion from goblet cells in the guinea pig respiratory epithelium. Exp. Lung Res. 1990, 16, 711–725.
- BISGAARD, H., and PEDERSEN, M. SRS-A leukotrienes decrease the activity of human respiratory cilia. Feder. Proc. Am. Soc. Exp. Biol. 1983, 42, 1381. Abstract 6381; LUNDGREN, J. D., SHELHAMER, J. H. and KALINER, M. A. The role of eicosanoids in respiratory mucus hypersecretion. Ann. Allergy 1985, 55, 5–8, 11.
- LEIKAUF, G. D., CLAESSON, H. E., DOUPNIK, C. A., HYBBINETTE, S. and GRAFTSTROM, R. C. Cysteinyl leukotrienes enhance growth of human airway epithelial cells. Am. J. Physiol. 1990, 259, L255–L261.
- (a) MUNOZ, N. M., DOUGLAS, I., MAYER, D., HERRNREITER A., ZHU, X., and LEFF. A. R. Eosinophil chemotaxis inhibited by 5-lipoxygenase blockade and leukotriene receptor antagonism. Am. J. Respir. Crit. Care Med. 1997, 155, 1398–1403; (b) BUSSE, W. W. Leukotrienes and Inflammation. Am. J. Respirol. Crit. Care Med. 1998, 157, S210–S213.
- CHUNG, K. F. Role of inflammation in the hyperreactivity of the airways in asthma. Thorax 1986, 41, 657–662.
- (a) BLOOMQUIST, E. I., and KREAM, R. M. Release of substance P from guinea-pig trachea leukotriene D4. Exp. Lung Res. 1990, 16, 645–659; (b) ELLIS, J. L., and UNDEM, B. J. Role of peptidoleukotrienes in capasaicin-sensitive sensory fibre-mediated responses in guinea-pig airways. J. Physiol. (London) 1991, 436, 469–484; (c) BISGAARD, H., GROTH, S., and MADSEN, F., Bronchial hyperreactivity to leucotriene D4 and histamine in exogenous asthma. Br. Med. J. 1985, 290, 1468–1471.
- HENDERSON, W. R.JR. The role of leukotrienes in inflammation. Ann. Internal Med. 1994, 121, 684–698.
- (a) OOSAKI, R., MIZUSHIMA, Y., KAWASAKI, A., KASHII, T., MITA, H., SHIDA, T., AKIYAMA, K., and KOBAYASHI, M. Urinary excretion of leukotriene E4 and 11-dehydrothromboxane B2 in patients with spontaneous asthma attacks. Int. Arch. Allergy Immunol. 1997, 114, 373–378; (b) KUMLIN, M., DAHLÉN, B., BJÖRCK, T., ZETTERSTRÖM, O., GRANSTRÖM, E., and DAHLÉN, S.E. Urinary excretion of leukotriene E4 and 11-dehydrothromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics. Am. Rev. Respir. Dis. 1992, 146, 96–103.
- MACHADO, E. R., UETA, M. T., LOURENÇO, E. V., ANIBAL, F. F., SORGI, C. A., SOARES, E. G., ROQUE-BARREIRA, M. C., MEDEIROS, A. I., and FACCIOLI, L. H. Leukotrienes play a role in the control of parasite burden in murine strongyloidiasis. J. Immunol. 2005, 175, 3892–3899.
- LEMKE, T. L., and WILLIAMS, D.A. in Foyles Principles of Medicinal Chemistry; 5th edition, (ed. William O. Foye) Chapter 33, Lippincott, Williams and Wilkins, Philadelphia, 2008, p. 889.
- NORRIS, A. A. Pharmacology of sodium cromoglycate. Clin. Exp. Allergy 1996, 26, s5–s7.
- FORD-HUTCHINSON, A. W., GRESSER, M., and YOUNG, R. N. 5-Lipoxygenase. Ann. Rev. Biochem. 1994, 63, 383–417.
- ORNING, L., and HAMMARSTRÖM, S. Inhibition of leukotriene C and leukotriene D biosynthesis. J Biol. Chem. 1980, 255, 8023–8026.
- BERNSTRÖM, K., and HAMMARSTRÖM, S. Metabolism of leukotriene D by porcine kidney, J. Biol. Chem. 1981, 256, 9573–9578.
- (a) BUCKNER, C. K., KRELL, R. D., LARAVUSO, R. B., COURSIN, D. B., BERNSTEIN, P. R., and WILL, J.A. Pharmacological evidence that human intralobar airways do not contain different receptors that mediate contractions to leukotriene C4 and leukotriene D4. J. Pharmacol Exp Thera., 1986, 237, 558–562; (b) COLEMAN, R. A., R. M. EGLEN, R.L. JONES J, NARUMIYA S., SHIMIZU T., SMITH W. L., DAHLÉN S.-E., DRAZEN J. M., GARDINER P. J., JACKSON W. T., JONES T. R., KRELL R. D., and NICOSIA S. Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature. Adv. Prostaglandin Thromboxane Leukotriene Res. 1995, 23, 283–285.
- LYNCH, K. R., O'NEILL, G. P., LIU, Q., IM, D. S., SAWYER, N., METTERS, K. M., COULOMBE, N., ABRAMOVITZ, M., FIGUEROA, D. J., ZENG, Z., CONNOLLY, B. M., BAI, C., AUSTIN, C. P., CHATEAUNEUF, A., STOCCO, R., GREIG, G. M., KARGMAN, S., HOOKS, S. B., HOSFIELD, E., WILLIAMS, D. L. JR., FORD-HUTCHINSON, A. W., CASKEY, C. T. and EVANS, J. F. Characterization of the human cysteinyl leukotriene CysLT1receptor. Nature 1999, 399, 789–793.
- YOUNG R. N. Inhibitors of 5-lipoxygenase: a therapeutic potential yet to be realized? Eur. J. Med. Chem. 1999, 34, 671–685.
- (a) MILLER, D. K., GILLARD, J. W., VICKERS, P.J., SADOWSKI, S., LÉVEILLÉ, C., MANCINI, J. A., CHARLESON, P., DIXON, R. A. F., FORD-HUTCHINSON, A. W., FORTIN, R., GAUTHIER, J. Y., RODKEY, J., ROSEN, R., ROUZER, C., SIGAL, I. S., STRADER, C. D., and EVANS, J.F. Identification and isolation of a membrane protein necessary for leukotriene production. Nature 1990, 343, 278–281; (b) DIXON, R. A. F., DIEHL, R. E., OPAS, E., RANDS, E., VICKERS, P. J., EVANS, J. F., GILLARD, J.W., and MILLER, D. K. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 1990, 343, 282–284.
- GILLARD, J., FORD-HUTCHINSON, A. W., CHAN, C. C., CHARLESON, S., DENIS, D., FOSTER, A, FORTIN, R, LEGER, S, MCFARLANE, C. S., MORTON, H., PIECHUTA, H., RIENDEAU, D., ROUZER, C. A., ROKACH, J., YOUNG, R., MACINTYRE, D. E., PETERSON, L., BACH, T., EIERMANN, G., HOPPLE, S., HUMES, J., HUPE, L., LUELL, S., METZGER, J., MEURER, R., MILLER, D. K., OPAS, E., and PACHOLOK, S. L-663, 536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2, 2-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Canadian J. Physiol. Pharmacol. 1989, 67, 456–464.
- PRASIT, P., BELLEY, M., BLOUIN, M., BRIDEAU, C., CHAN, C., CHARLESON, S., EVANS, J. F., FRENETTE, R., GAUTHIER, J. Y., GUAY, J., GILLARD, J. W., GRIMM, E., FORDHUTCHINSON, A. W., HUTCHINSON, J. H., FORTIN, R., JONES, T. R., MANCINI, J., LEGER, S., MCFARLANE, C. S., PIECHUTA, H., RIENDEAU, D., ROY, P., TAGARI, P., VICKERS, P. J., YOUNG, R. N., and ZAMBONI, R.A. New class of leukotriene biosynthesis inhibitors: the discovery of MK-0591, J. Lipid Mediators. 1993, 6, 239–244.
- WENZEL, S. E., and KAMADA, A. K. Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma. Ann. Pharmacother. 1996, 30, 858–864.
-
VARGHESE, M., and LOCKEY, R. F. Aspirin-exacerbated asthma. Allergy Asthma Clin. Immunol. 2006, 4, 75–83.
10.1186/1710-1492-4-2-75 Google Scholar
- (a) ADAMS, G.K., and LICHENSTEIN, L. M. Antagonism of antigen-induced contraction of guinea pig and human airways. Nature 1970, 270, 255–257; (b) SHEARD, P., LEE, T.B., and TATTERSALL, M.L. Further studies on the SRS-A antagonist FPL 55712. Monogr. Allergy. 1977, 12, 245.
- (a) PONG, S-S., and DEHAVEN, R. N. Characterization of a leukotriene D4 receptor in guinea pig lung. Proc. Natl. Acad. Sci. USA. 1983, 80, 7415–7419; (b) LEWIS, M. A., MONG, S., VESSELLA, R. A., and CROOKE, S.T. Identification and characterization of leukotriene D4 receptors in adult and fetal human lung, Biochem. Pharmacol. 1985, 34, 4311–4317.
- PIPER, P. J., SAMHOUN, M. N., TIPPINS, J. R., WILLIAMS, T. J., PALMER, A., and PECK, M. J. Pharmacological studies on pure SRS-A, SRS and synthetic leukotriene C4 and D4. in SRS-A and Leukotrienes. (ed P. J. Piper) Wiley, Chichester, 1981, pp. 81–99.
- BRUNET, G., PIECHUTA, H., HAMEL, R., HOLME, G., and FORD-HUTCHINSON, A. W. Respiratory responses to leukotrienes and biogenic amines in normal and hyperreactive rats, J. Immunol. 1983, 131, 434–438.
- MCFARLANE, C. S., PIECHUTA, H., HALL, R. A., and FORDHUTCHINSON, A. W. Effects of a contractile prostaglandin antagonist (L-640, 035) upon allergen-induced bronchoconstriction in hyperreactive rats and conscious squirrel monkeys. Prostaglandins 1982, 131, 434–438.
- ABRAHAM, N. M., DELEHUNT, J. C., YERGER, L., and MARCHETT, E. B. Characterization of late-phase response after antigen challenge in allergic sheep. Am. Rev. Respir. Dis. 1983, 128, 839–844.
- YOUNG, R. N. Structural analysis of sulfido-peptide leukotrienes: application to the design of potent and specific antagonists of leukotriene D4. Adv. Prostaglandin Thromboxane Leukotriene Res. 1987, 19, 643–646.
- (a) GIRARD, Y., and ROKACH, J.Leukotriene antagonists 1988, US Patent #4.761, 425; (b) COOMBS, W., FRENETTE, R., GUINDON, Y., andYOUNG, R.N. Unpublished results.
- GLEASON, J. G., HALL, R. F., PERCHONOCK, C. D., ERHARD, K. F., FRAZEE, J. S., KU, T. W., KONDRAD, K., MCCARTHY, M. E., MONG, S., CROOKE, S. T., CHI-ROSSO, G., WASSERMAN, M. A., TORPHY, T. J., MUCCITELLI, R. M., HAY, D. W., TUCKER, S. S. and VICKERY-CLARK, L. High-affinity leukotriene receptor antagonists. Synthesis and pharmacological characterization of 2-hydroxy-3-[(2-carboxyethyl)thio]-3-[2-(8-phenyloctyl)phenyl] propanoic acid. J. Med. Chem. 1987, 30, 959–961.
- CHRISTIE, P. E., SMITH, C. M., and LEE, T. H. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. Am. Rev. Respir. Dis. 1991, 144, 957–958.
- NAKAGAWA, N., OBATA, T., KOBAYASHI, T., OKADA, Y., NAMBU, F., TERAWAKI, T., and AISHITA, H. In vivo pharmacologic profile of ONO-1078: a potent, selective and orally active peptide leukotriene (LT) antagonist Japan. J. Pharmacol. 1992, 60, 217–225.
- JONES, T. R., YOUNG, R. N., CHAMPION, E., CHARETTE, L., DENIS, D., FORD-HUTCHINSON, A. W., FRENETTE, R., GAUTHIER, J. Y., GUINDON, Y., KAKUSHIMA, M., MASSON, P., MCFARLANE, C., PIECHUTA, H., ROKACH, J. and ZAMBONI, R. L-649, 923, Sodium (βS*, γR*)-4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propylthio)-γ-hydroxy-β-methylbenzenebutanoate, a selective, orally active leukotriene receptor antagonist. Can. J. Physiol. Pharmacol. 1986, 64, 1068–1075.
- JONES, T. R., GUINDON, Y., YOUNG, R. N., CHAMPION, E., CHARETTE, L., DENIS, D., ETHIER, D., HAMEL, P., FORDHUTCHINSON, A. W., FORTIN, R., LETTS, G., MASSON, P., MCFARLANE, C., PIECHUTA, H., ROKACH, J., YOAKIM, C., DEHAVEN, R. N., MAYCOCK, A. and PONG, S-S. L-648, 051, sodium 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propylsulfonyl]-γ-oxobenzenebutanoate: a leukotriene D4 receptor antagonist. Can. J. Physiol. Pharmacol. 1986, 64, 1535–1542.
- MONG, S., WU, H. L., SCOTT, M. O., LEWIS, M. A., CLARK, M. A., WEICHMAN, B. M., KINZIG, C. M., GLEASON, J. G., and CROOKE, S. T. Molecular heterogeneity of leukotriene receptors: correlation of smooth muscle contraction and radioligand binding in guinea-pig lung. J. Pharmacol. Exp. Ther. 1985, 234, 316–325.
- YOUNG R. N. The development of new anti-leukotriene drugs: L-648, 051 and L-649, 923, specific leukotriene D4 antagonists. Drugs Future 1988, 13, 745–759.
- SANDERS, J. E., EIGENBERG, D. A., BRACHT, L. J., WANG, W. R., and VAN ZWIETEN M. J. Thyroid and liver trophic changes in rats secondary to liver microsomal enzyme induction caused by an experimental leukotriene antagonist (L-649, 923). Toxicol. Appl. Pharmacol. 1988, 95, 378–387.
- BARNES, N., PIPER, P. J., and COSTELLO, J. The effect of an oral leukotriene antagonist L-649, 923 on histamine and leukotriene D4-induced bronchoconstriction in normal man. J. Allergy Clin. Immunol. 1987, 79, 816–821.
- BRITTON, R., HANLEY, S. P., and TATTERSFIELD A. E. The effect of an oral leukotriene D4 antagonist L-649, 923 on the response to inhaled antigen in asthma. J. Allergy Clin. Immunol. 1987, 79, 811–816.
- EVANS, J. M., BARNES, N. C., ZAKRZEWSKI, J. T., SCIBERRAS, D. G., STAHL, E. G., PIPER, P. J., and COSTELLO, J. F. L-648, 051, a novel cysteinylleukotriene antagonist is active by the inhaled route in man. Br. J. Clin. Pharmacol. 1989, 28, 125–135.
- BEL, E. H., TIMMERS, M. C., DIJKMAN, J. H., STAHL, E. G., and STERK, P. J. The effect of an inhaled leukotriene antagonist, L-648, 051, on early and late asthmatic reactions and subsequent increase in airway responsiveness in man. J. Allergy Clin. Immunol. 1990, 85, 1067–1075.
- MARSHALL, W. S., GOODSON, T., CULLINAN, G. J., SWANSON-BEAN, D., HAISCH, K. D., RINKEMA, L. E., and FLEISCH, J. H. Leukotriene receptor antagonists. 1. Synthesis and structure-activity relationships of alkoxyacetophenone derivatives. J. Med. Chem. 1987, 30, 682–689.
- FULLER, R. F., BLACK, P. N., and DOLLERY, C. T. Effect of the oral leukotriene D4 antagonist LY171883 on inhaled and intradermal challenge with antigen and leukotriene D4 in atopic subjects. J. Allergy Clin. Immunol. 1998, 83, 939–944.
- ISRAEL, E., JUNIPER, E. F., CALLAGHAN, J. T., MATHUR, P. N., MORRIS, M. M., DOWELL, A. R., ENAS, G. G., HARGREAVE, F. E., and DRAZEN, J. M. Effect of a leukotriene antagonist, LY171883, on cold air-induced broncho-constriction in asthmatics. Am. Rev. Respir. Dis. 1989, 140, 1348–1353.
- ZAMBONI, R., BELLEY, M., CHAMPION, E., CHARETTE, L., DEHAVEN, R., FRENETTE, R., GAUTHIER, J. Y., JONES, T. R., LEGER, S., MASSON, P., MCFARLANE, C. S., METTERS, K., PONG, S. S., PIECHUTA, H., ROKACH, J., THERIEN, M., WILLIAMS, H. W. R., and YOUNG, R. N. Development of a novel series of styrylquinoline compounds as high-affinity leukotriene D4 receptor antagonists: synthetic and structure–activity studies leading to the discovery of (+/−)-3-[[[3-[2-(7-chloro-2-quinolinyl)-(E)-ethenyl] phenyl][[3-(dimethylamino)-3-oxopropyl]thio]methyl] thio]propionic acid. J. Med. Chem. 1992, 35, 3832–3844.
- PERCHONOCK, C. D., MCCARTHY, M. E., ERHARD, K.F., GLEASON, J. G., WASSERMAN, M. A., MUCCITELLI, R. M., DEVAN, J. F., TUCKER, S. S., and VICKERY, L.M. Synthesis and pharmacological characterization of 5-(2-dodecylphenyl)-4, 6-dithianonanedioic acid and 5-[2-(8-phenyloctyl)phenyl]-4, 6-dithianonanedioic acid: prototypes of a novel class of leukotriene antagonists. J. Med. Chem. 1985, 28, 1145–1147.
- YOUNG, R. N., ZAMBONI, R., BELLEY, M., CHAMPION, E., CHARETTE, L., DEHAVEN, R., FRENETTE, R., FORDHUTCHINSON, A. W., GAUTHIER, J. Y., JONES, T.R., LEGER, S., MCFARLANE, C. S., MASSON, P., PIECHUTA, H., PONG, S. S., ROKACH J., and WILLIAMS, H. L-660, 711: a potent selective and orally active antagonist of leukotriene D4. in New Trends in Lipid Mediators Research (eds U. Zor, Z. Naor, A. Danon) Basel, Karger, 1989, Vol. 3, pp. 62–66.
- JONES, T. R., ZAMBONI, R., BELLEY, M., CHAMPION, E., CHARETTE, L., FORD-HUTCHINSON, A. W., FRENETTE, R., GAUTHIER, J. Y., LEGER, S., MASSON, P., MCFARLANE, C. S., PIECHUTA, H., ROKACH, J., WILLIAMS, H., YOUNG, R. N., DEHAVEN R. N., and PONG, S. S. Pharmacology of L-660, 711 (MK-571): a novel potent and selective leukotriene D4 receptor angatonist. Can. J. Physiol. Pharmacol. 1989, 67, 17–28.
- SOLÉR, M., SIELCZAK, M., and ABRAHAM, W. M. Separation of late bronchial responses from airway hyperresponsiveness in allergic sheep. J. Appl. Physiol. 1991, 70, 617–623.
- ABRAHAM, W. M., and STEVENSON, J. S. Lung inflammatory cell changes after local antigen-challenge in allergic sheep with and without late airway responses. FASEB J., 1988, 2, a1057.
- MCNAMARA, J. M., LEEZER, J. L., BHUPATHY, M., AMATO, J. S., REAMER, R. A., REIDER, P. J., and GRABOWSKI, E.J.J. Synthesis of unsymmetrical dithioacetals: an efficient synthesis of a Novel LTD4 antagonist, L-660, 711. J. Org. Chem. 1989, 54, 3718–3721.
-
MARGOSKI, D. J. Clinical experience with MK-571: a potent and specific LTD4 receptor antagonist. Ann. New York Acad. Sci. 1991. 629, 148–156.
10.1111/j.1749-6632.1991.tb37972.x Google Scholar
- DEPRÉ, M., MARGOLSKEE, D. J., HECKEN, A., HSIEH, J.S. Y., BUNTINX, A., DE SCHEPPER, P. J., and ROGERS, J. D. Dose-dependent kinetics of the enantiomers of MK- 571, an LTD4-receptor antagonist. Eur. J. Clin. Pharmacol. 1992, 43, 431–433.
- DEPRÉ, M., MARGOLSKEE, D. J., HSIEH, J. Y., VAN HECKEN, A., BUNTINX, A., DE LEPELEIRE, I., ROGERS, J. D. and DE SCHEPPER, P. J. Plasma drug profiles and tolerability of MK-571 (L-660, 711): a leukotriene D4 receptor antagonist, in man. Eur. J. Clin. Pharmacol. 1992, 43, 427–430.
- GADDY, J. N., MARGOLSKEE, D. J., BUSH, R. K., WILLIAMS, V. C., and BUSSE, W. W. Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma. Am. Rev. Respir. Dis. 1992, 146, 358–363.
-
GADDY, J., MCCREEDY, W., MARGOLSKEE, D., WILLIAMS, V., and BUSSE, W. A potent leukotriene D4 antagonists (MK-571) significantly reduces airway obstruction in mild to moderate asthma. J. Allergy Clin. Immunol. 1991, 87, 308.
10.1016/0091-6749(91)91958-V Google Scholar
-
MARGOLSKEE, D., BODMAN, S., DOCKHORN, R., ISRAEL. E., KEMP, J., MANSMANN, H., MINOTTI, D. A., SPECTOR, S., STRICKER, W., TINKELMAN, D., TOWNLEY, R., WINDER, J., and WILLIAMS, V. The therapeutic effects of MK-571 a potent and selective leukotriene (LT)D-4 receptor antagonist in patients with chronic asthma [abstract]. J. Allergy Clin. Immunol. 1991, 87, 309.
10.1016/0091-6749(91)91959-W Google Scholar
- GROSSMAN, S. J., DELUCA, J. G., ZAMBONI, R. J., KEENAN, K. P., PATRICK, D. H., HEROLD, E. G., VAN ZWIETEN, M. J., and ZACCHEI, A. G. Enantioselective induction of peroxisomal proliferation in CD-1 mice by leukotriene antagonists. Toxicol. Appl. Pharmacol. 1992, 116, 217–224.
- EACHO, P. I., FOXWORTHY, P. S., JOHNSON, W. D., HOOVER, D. M., and WHITE, S. L. Hepatic peroxisomal changes induced by a tetrazole-substituted akoxyacetophenone in rats and comparison with other species. Toxicol. Appl. Pharmacol. 1986, 83, 430–437.
- MOODY, D. E., REDDY, J. K., LAKE, B. G., POPP, J. A., and REESE, D. H. Peroxisome proliferation and nongenotoxic carcinogenesis: commentary on a symposium. Fundamental Appl. Toxicol. 1991, 6, 233–248.
- NAGAI, H., SHIMAZAWA, T., YAKUO, I., AOKI, M., KODA, A., and KASAHARA, M. Role of peptide-leukotrienes in liver injury in mice. Inflammation 1989, 13, 673–680.
- YOUNG, R. N., GAUTHIER, J. Y., THÉRIEN M., and ZAMBONI, R. Asymmetric dithioacetals III: the preparation of the enantiomers of 3-(((3-(2-(7-chloroquinolin-2-yl)-(E) -ethenyl) phenyl)3-dimethylamino-3-oxopropylthio)methyl)thio) propionic acid (L-660, 711). An antagonist of leukotriene D4. Heterocycles 1989, 28, 967.
- GAUTHIER, J. Y., JONES, T., CHAMPION, E., CHARETTE, L., DEHAVEN, R., FORD-HUTCHINSON, A. W., HOOGSTEEN, K., LORD, A., MASSON, P., PIECHUTA, H., PONG, S. S., SPRINGER, J. P., THÉRIEN, M., ZAMBONI, R., and YOUNG, R. N 3-((((3-(2-(7-Chloroquinolin-2-yl-(E)-ethenyl) phenyl)-3-dimethylamino-3-oxopropylthio)methyl) thio)propionic acid: a potent and specific leukotriene D4 receptor antagonist, stereospecific synthesis, assignment of absolute configuration and biological activity of the entantiomers. J. Med. Chem. 1990, 33, 2841–2845.
- BHUPATHY, M., HUGHES, D. L., AMATO, J. S., BERGAN, J. J., LEAZER, J. L., LOVELACE, T. C., MCNAMARA, J. M., REAMER, R. A., SIDLER, D. R., GRABOWSKI, E. J. J., REIDER, P. J. and SHINKAI, I. Chemoenzymatic synthesis of a novel LTD4 antagonist. Pure Appl. Chem. 1992, 64, 1939–1944.
- CHENG, H., SCHWARTZ, J. I., LIN, C., AMIN, R. D., SEIBOLD, R. J., LASSETER, K. C., EBEL, D. L., TOCCO, D. J., and ROGERS, D. J. The bioavailability and nonlinear pharmacokinetics of MK-679 in humans. Biopharma. Drug Dispos. 1994, 15, 409–418.
- IMPENS, N., REISS, T. F., TEAHAN, J. A., DESMET, M., ROSSING, T. H., SHINGO, S., ZHANG, J., SCHANDEVYL, W., VERBESSELT, R., and DUPONT. A. G. Acute bronchodilation with intravenously administered leukotriene D4 receptor antagonist, MK-0679. Am. Rev. Respir. Dis. 1993, 147, 1442–1446.
- DAHLEN, B., D. J. MARGOLSKEE, O. ZETTERSTROM, and S.-E. DAHLEN. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax 1993, 48: 1205–1210.
- CHRISTIE, P. E., TAGARI, P., FORD-HUTCHINSON, A. W., CHARLESSON, S., CHEE, P., ARM, J. P., and LEE, T.H. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am. Rev. Respir. Dis. 1991, 143, 1025–1029.
- DAHLEN, B., KUMLIN, M., MARGOLSKEE, D. J., LARSSON, C., BLOMQVIST, H., WILLIAMS, V. C., ZETTERSTROM, O., and DAHLEN. S.-E. The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin sensitive asthmatics. Eur. Respir. J. 1993, 6, 1018–1026.
- MARGOLSKEE, D., FRIEDMAN, B., WILLIAMS, V., BOTTO, A., NOONAN, N., ALTMAN, L., BONE, R., DOCKHORN, R., ELLIS, E., ESCHENBACHER, W., FINDLAY, S., GRANT, J., GROSSMAN, J., HENDLES, L., IZRAEL, E., KEMP, J., NELSON, H., PEARLMAN, D., STRICKER, W., TINKELMAN, D., TOWNLEY R., VANDEWALKER, M., WANDERER, A., WEISBERG, G., and WINDER, J. The therapeutic effects of MK-0679: a selective leukotriene D4 receptor antagonist, in patients with chronic asthma. 8th International Conference on Prostaglandins and Related Compounds, 1992, July 26–31, Montreal, Abstract 639.
- NICOLL-GRIFFITH, D., YERGEY, J., TRIMBLE, L., WILLIAMS, H., RASORI, R. and ZAMBONI, R. In vitro and in vivo biotransformations of the potent leukotriene D4 antagonist verlukast in the rat. Drug Metab. Dispos. 1992, 20, 383–389.
- NICOLL-GRIFFITH, D. A., GUPTA, N., TWA, S.P.WILLIAMS, H., TRIMBLE L. A., and YERGEY J. A. Verlukast (MK-0679) conjugation with glutathione by rat liver and kidney cytosols and excretion in the bile. Drug Metab. Dispos. 1995, 23, 1085–1093.
- LABELLE, M., PRASIT, P., BELLEY, M., BLOUIN, M., CHAMPION, E., CHARETTE, L., DELUCA, J. G., DUFRESNE, C., FRENETTE, R., GAUTHIER, J. Y., GRIMM, E., GROSSMAN, S. J., GUAY, D., HEROLD, E. G., JONES, T. R., LAU, C. K., LEBLANC, Y., LEGER, S., LORD, A., MCAULIFFE, M., MCFARLANE, C., MASSON, P., METTERS, K. M., OUIMET, N., PATRICK, D. H., PERRIER, H., PICKETT, C. B., PIECHUTA, H., ROY, P., WILLIAMS, H., WANG, Z., XIANG, Y. B., ZAMBONI, R. J., FORDHUTCHINSON, A. W. and YOUNG, R. N. The discovery of a new structural class of potent orally active leukotriene D4 antagonists. Bioorg. Med. Chem. Lett. 1992, 2, 1141–1146.
- LABELLE, M., BELLEY, M., CHAMPION, E., GORDON, R., HOOGSTEEN, K., JONES, T. R., LEBLANC, Y., LORD, A., MCAULIFFE, M., MCFARLANE, C., MASSON, P., METTERS, K. M., NICOLL-GRIFFITH, D., OUIMET, N., PIECHUTA, H., ROCHETTE, C., SAWYER, N., XIANG, Y. B., YERGEY, J., FORD-HUTCHINSON, A. W., PICKETT, C. B., ZAMBONI, R.J. and YOUNG, R. N. The discovery of L-699, 392, a novel potent and orally active leukotriene D4 receptor antagonist. Bioorg. Med. Chem. Lett. 1994, 4, 463–468.
- GROSSMAN, S. J., DELUCA, J. G., ZAMBONI, R. J., KECNAN, K. P., PATRICK, D. H., HEROLD, E. G., VAN ZWIETEN, M. J., and ZACCHEI, A. G. Enantioselective induction of peroxisomal proliferation in CD-1 mice by leukotriene antagonists. Toxicol. Appl. Pharmacol. 1992, 116, 217.
- LAZAROW, P. B., and DE DUVE, C. A fatty acyl-CoA oxidizing system in rat liver peroxisomes; enhancement by clofibrate, a hypolipidemic drug. Proc. Natl Acad. Sci. USA 1976, 73, 2043.
- HASHIMOTO, T., in Peroxisomes in Biology and Medicine, (eds H. D. Fahimi and H. Sies) Springer Verlag, Berlin, 1987, pp. 97–104.
- GREEN, S. Receptor-mediated mechanisms of peroxisome proliferators. Biochem. Pharmacol. 1992, 43, 393–401.
- ZHU, Y., ALVARES, K., HUANG, Q., RAO, M. S. and REDDY, J. K. Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. J. Biol. Chem. 1993, 268, 26817–26820.
- LABELLE, M., BELLEY, M., GAREAU, Y., GAUTHIER, J. Y., GUAY, D., GORDON, R., GROSSMAN, S. G., JONES, T. R., LEBLANC, Y., MCAULIFFE, M., MCFARLANE, C., MASSON, P., METTERS, K. M., OUIMET, N., PATRICK, D. H., PIECHUTA, H., ROCHETTE, C., SAWYER, N., XIANG, Y. B., PICKETT, C. B., FORD-HUTCHINSON, A. W., ZAMBONI, R. J. and YOUNG, R. N. Discovery of MK-0476: a potent and orally active leukotriene D4 receptor antagonist devoid of peroxisomal enzyme induction. Bioorg. Med. Chem. Lett. 1995, 5, 283–288.
- JONES, T. R., LABELLE, M., BELLEY, M., CHAMPION, E., CHARETTE, L., EVANS, J., FORD-HUTCHINSON, A. W., GAUTHIER, J. Y., LORD, A., MASSON, P., MCAULIFFE, M., MCFARLANE, C. S., METTERS, K. M., PICKETT, C., PIECHUTA, H., ROCHETTE, C., RODGER, I. W., SAWYER, N., YOUNG, R. N., ZAMBONI, R. and ABRAHAM, W.M. Pharmacology of montelukast sodium (Singulair™), a potent and selective leukotriene D4 receptor antagonist. Can. J. Physiol. Pharmacol. 1995, 73, 191–201.
- MELPOLER, J. B., and HECK, R. F. Palladium-catalyzed arylation of allylic alcohols with aryl halides. J. Org. Chem. 1976, 41, 265.
- COREY, E. J., BAKSHI, R. K., RAMAN, K., and SHIBATA, S. Highly enantioselective borane reduction of ketones catalyzed by chiral oxazaborolidines. Mechanism and synthetic implications. J. Am. Chem. Soc. 1987, 109, 5551.
- MATHRE, D. J., JONES, T. K., XAVIER, L. C., BLAELDOCK, T. J., REAMER, R. A., MOHAN, J. J., TURNER JONES, E.T., HOOGSTEEN, K., BAUM, M. W., and GRABOWSKI, E.J.J. A practical enantioselective synthesis of alpha, alpha-diaryl-2-pyrrolidinemethanol. Preparation and chemistry of the corresponding oxazaborolidines. J. Org. Chem. 1991, 56, 751.
- KING, A. O., CORLEY, E. G., ANDERSON, R. K., LARSEN, R. D., VERHOEVEN, T. R., REIDER, P. J., XIANG, Y. B., BELLEY, M., LEBLANC, Y., LABELLE, M., PRASIT, P., and ZAMBONI, R. J., An efficient synthesis of LTD4 antagonist L-699, 392. J. Org. Chem. 1993, 58, 3731–3735.
- BHUPATHY, M., MCNAMARA, J. M., SIDLER, D. R., VOLANTE, R., and BERGAN, J. Process for the preparation of leukotriene anatgonists. US patent # 5614632, March 25, 1997.
- CHAURET, N., YERGEY, J., TRIMBLE, L., and NICOLLGRIFFITH D. In vitro biotransformation of MK-0476, a new potent LTD4 antagonist. in Proceedings of the 10th International Symposium on Microsomes and Drug Oxidations, 1994, 22, p. 612.
- DUFRESNE C., GALLANT M., GAREAU Y., RUEL R., TRIMBLE L., and LABELLE M. Synthesis of montelukast (MK-0476) metabolic oxidation products. J. Org. Chem. 1996, 61, 8518–8525.
- BALANI, S. K., XU, PRATHA, X. V., KOSS, M. A., AMIN, R. D., DUFRESNE, C., MILLER, R. R., ARISON, B. H., DOSS, G. A., CHIBA, M., FREEMAN, A., HOLLAND, S. D., SCHWARTZ, J. I., LASSETER, K. C., GERTZ, B. J., ISENBERG, J. I., ROGERS, J. D., LIN, J. H., and BAILLIE. T. A. Metabolic profiles of montelukast sodium (Singulair): a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile. Drug Metab. Dispos. 1997, 25, 1282–1287.
- CHIBA M., XU X., NISHIME J. A., BALANI S. K., and LIN J. H. Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans. Drug Metab. Disposl 1997, 25, 1022–1031.
- Drug Approval Package: Singulair (Montelukast Sodium) NDA# 020829 [http://www.accessdata.fda. gov/drugsatfda_docs/nda/98/020829s000_Singulair TOC.cfm]
- SCHOORS, D. F., DE SMET, M., REISS, T., MARGOLSKEE, D., CHENG, H., LARSON, P., AMIN, R., and SOMERS, G. Single dose pharmacokinetics, safety and tolerability of MK-0476, a new leukotriene D4-receptor antagonist, in healthy volunteers. Br. J. Clin. Pharmacol. 1995, 40, 277–280.
- CHENG, H., LEFF, J. A., AMIN, R., GERTZ, B. J., DE SMET, M., NOONAN, N., ROGERS, J. D., MALBECQ, W., MEISNER, D., and SOMERS, G. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharma. Res. 1996, 13, 445–448.
- ZHAO, J. J., ROGERS, J. D., HOLLAND, S. D., LARSON, P., AMIN, J. D., HAESEN, R., FREEMAN, A., MERZ, S. M., and CHENG, H. Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. Biopharma. Drug Dispos. 1997, 18, 743–824.
- KNORR, B., LARSON, P., NGUYEN, H. H., HOLLAND, S., REISS, T.F., CHERVINSKY, P., BLAKE, K., VAN NISPEN, C. H., NOONAN, G., FREEMAN, , A., HAESEN, R., MICHIELS, N., ROGERS, J. D., AMIN, R. D., ZHAO, J., XU, X., SEIDENBERG, B. C., GERTZ, B. J., and SPIELBERG, S. Montelukast dose selection in 6- to 14-year-olds: comparison of single-dose pharmacokinetics in children and adults, J. Clin. Pharmacol. 1999, 39, 786–793.
- STORMS, W., MICHELE, T. M., KNORR, B., NOONAN, G., SHAPIRO, G., ZHANG, J., SHINGO, S., and REISS. T.F. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged ≥ 6 years. Clin. Exp. Allergy 2001, 31, 77–87.
- COBB, D.B. ABBOT, C. L., WATSON, W. A., and FERNANDEZ, M. C. High-dose montelukast exposures in a 3-year-old and a 5-year-old child. Veter. Human Toxicol. 2002, 44, 91–92.
- DE LEPELEIRE, I., REISS, T.F., ROCHETTE, F., BOTTO, A., JZHANG, J., KUNDU, K., and DECRAMER, M. Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma. Clin. Pharmacol. Thera. 1997, 61, 83–92.
- DIAMANT, Z., GROOTENDORST, D. C., VESELIC-CHARVAT, M., TIMMERS, C., DE SMET, M., LEFF, J. A., SEIDENBERG, B. C., ZWINDERMAN, A. H., PESZEK, I., and STERK, P.J. The effect of montelukast (Mk-0476): a cysteinyl leukotriene receptor antagonist, on allergen-induced airway Responses and sputum cell counts in asthma. Clin. Exp. Allergy 1999, 29, 42–51.
- REISS, T.F., HILL, J. B., HARMAN, E., ZHANG, J., TANAKA, W. K., BRONSKY, E., GUERREIRO, D., and HENDELES. L. Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax 1997, 52, 1030–1035.
- Singulair. [package insert].: Merck and Co, Inc, West Point, PA, 1999.
- ALTMAN, L. C., MUNK, Z., SELTZER, J., NOONAN, N., SHINGO, S., ZHANG, J. and REISS. TF. A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene–receptor antagonist. J. Allergy Clin. Immunol. 1998, 102, 50–55.
- NOONAN, M. J., CHERVINSKY, P., BRANDON, M., ZHANG, J., KUNDU, S., MCBURNEY, J., and REISS, T. J. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma: Montelukast Asthma Study Group. Eur. Respir. J. 1998, 11, 1232–1239.
- BRONSKY, E. A., KEMP, J. P., ZHAN, J., GUERREIRO, D., and REISS, T. F. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene–receptor antagonist, at the end of a once-daily dosing interval. Clin. Pharmacol. Thera. 1997, 62, 556–561.
-
KNORR, B., HOLLAND, S., ROGERS, J. D., NGUYEN, H. H., and REISS, T. F. Montelukast adult (10-mg film-coated tablet) and pediatric (5-mg chewable tablet) dose selections J. Allergy Clin. Immunol. 2000, 106, S172–S178.
10.1067/mai.2000.109424 Google Scholar
- REISS, T. F., KNORR, B., MALMSTROM, K., NOONAN, G., and LU, S. Clinical efficacy of montelukast in adults and children. Clin. Exp. Allergy Rev., 2001, 1, 264–273.
- REISS, T. F., CHERVINSKY, P., DOCKHORN, R. J., SHINGO, S., SEIDENBERG, B., and EDWARDS, T. B. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. A multicenter, randomized, double-blind trial. Arc. Internal Med. 1998, 158, 1213–1220.
- MALMSTROM, K., RODRIGUEZ-GOMEZ, G., and GUERRA, J. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial. Ann. Internal Med. 1999, 130, 487–495.
- KNORR, B., MATZ, J., BERNSTEIN, J. A., NGUYEN, J. H., SEIDENBERG, B. C., REISS, T. F., and BECKER, A. Montelukast for chronic asthma in 6- to 14-year old children. A randomized, double-blind trial. J. Am. Med. Assoc. 1998, 279, 1181–1186.
- WILLIAMS, B., NOONAN, G., REISS, T.F., KNORR, B., GUERRA, J., WHITE, R., and MATZ, J. Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older. Clin. Exp. Allergy 2001, 31, 845–854.
- KNORR, B., FRANCHI, L. M., BISGAARD, H., VERMEULEN, J. H., LESOUEF, P., SANTANELLO N., MICHELE, T. M., REISS, T. F., NGUYEN, H. H., and BRATTON, D. L. Montelukast: a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001, 108, e48.
- BECKER, A. B., KUZNETSOVA, O., VERMEULEN, J., SOTOQUIROS, M. E., YOUNG, B., REISS, T. F., DASS, S. B., and KNORR, B. A. Pediatric Montelukast Linear Growth Study Group. Linear growth in prepubertal asthmatic children treated with montelukast, beclomethasone, or placebo: a 56-week randomized double-blind study. Ann. Allergy Asthma Immunol. 2006, 96, 800–807.
- LAVIOLETTE, M., MALMSTROM, K., LU, S., CHERVINSKY, P., PUGET, J-P., PERSZEK, I., ZHANG, J. I., and REISS, T. F. Montelukast added to inhaled beclomethasone in treatment of asthma. Am. J. Respir. Crit. Care Med. 1999, 160, 1862–1868.
- LOFDAHL, C-G., REISS, T.F., LEFF, J. A., ISRAEL, E., NOONAN, M. J., FINN, A. F., SEIDENBERG, B. C., CAPIZZI, T., KUNDU, S., and GODARD, P. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. Br. Med. J. 1999, 319, 87–90.
- LEFF, J. A., ISRAEL, E., NOONAN, M. J., FINN, and GODARD, P., et al. Montelukast (MK-0476) allows tapering o of inhaled corticosteroids (ICS) in asthmatic patients while maintaining clinical stability. Am. J. Respir. Crit. Care Med. 1997, 155, A976 [abstract].
- WECHSLER, M. E., FINN, D., GUNAWARDENA, D., WESTLAKE, R., BARKER, A., HARANATH, S.P. PAUWELS, R. A., KIPS, J. C., and DRAZEN, J. M. Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest 2000, 117, 708–713.
- BILI, A., CONDEMI, J. J., BOTTONE, S. M., and RYAN, C.K. Seven cases of complete and incomplete forms of Churg-Strauss syndrome not related to leukotriene receptor antagonists. J. Allergy Clin. Immunol. 1999, 104, 1060–1065.
- WECHSLER, M. E., PAUWELS, R., and DRAZEN, J. M. Leukotriene modifiers and Churg-Strauss syndrome: adverse effect or response to corticosteroid withdrawal? Drug Safety 1999, 21, 241–251.
- PIZZICHINI, E., LEFF, J. A., REISS, T.F., HENDELES, L., BOULET, L. P., WEI, L. X., EFTHIMIADIS, A. E., ZHANG, J., and HARGREAVE, F. E. Montelukast reduces airway inflammation in asthma: a randomized, controlled trial. Eur. Respir. J. 1999, 14, 12–18.
- BISGAARD, H., LOLAND, L., and ANHÙJ, J. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am. J. Respir. Crit. Care Med. 1999, 160, 1227–1231.
- LAGOS, J. A., and MARSHALL, G. D. Montelukast in the management of allergic rhinitis. J. Thera. Clin. Risk Manag. 2007, 3, 327–332.
- NAYAK, A., and LANGDON, R. B. Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs 2007, 67, 887–901.
- BENFIELD, T. L., and LUNDGREN, J. D. PAF receptor antagonists in the treatment of asthma. Expert Opin. Invest. Drugs. 1994, 3, 733–742.
